Expression of tumor markers on breast and ovarian cancer cell lines

Anticancer Research

Volumn 23, Issue 2 A, 2003, Pages 1051-1055

  Kämmerer, Ulrike ^a,b   Thanner, Florian ^a   Kapp, Michaela ^a   Dietl, Johannes ^a   Sütterlin, Marc ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Cancer cell lines; Immunohistochemistry; Tumor markers

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD19 ANTIGEN; EPITHELIAL MEMBRANE ANTIGEN; ESTROGEN RECEPTOR; MUCIN 1; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR ANTIGEN; TUMOR MARKER;

ANTIGEN EXPRESSION; BREAST CANCER; CANCER CELL CULTURE; CANCER GRADING; CELL STRAIN MCF 7; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROSCOPY; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING;

EID: 0037524280     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Disis ML and Schiffman K: Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol 28: 12-20, 2001.
2. Kurebayashi J: Biological and clinical significance of HER2 overexpression in breast cancer. Breast Cancer 8: 45-51, 2001.
3. Luna-More S, Rius F, Weil B, Jimenez A, Bautista MD and Perez-Mellado A: EMA: a differentiation antigen related to node metastatic capacity of breast carcinomas. Pathol Res Pract 197: 419-425, 2001.
4. Scholl SM, Balloul JM, Le Goc G, Bizouarne N, Schatz C, Kieny MP, Mensdorff-Pouilly S, Vincent-Salomon A, Deneux L, Tartour E, Fridman W, Pouillart P and Acres B: Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer. J Immunother 23: 570-580, 2000.
5. Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, van Kamp GJ, Paul MA, Van Diest PJ, Meijer S and Hilgers J: Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18: 574-583, 2000.
6. Schlom J, Kantor J, Abrams S, Tsang KY, Panicali D and Hamilton JM: Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer. Breast Cancer Res Treat 38: 27-39, 1996.
7. Alters SE, Gadea JR and Philip R: Immunotherapy of cancer. Generation of CEA-specific CTL using CEA peptide pulsed dendritic cells. Adv Exp Med Biol 417: 519-524, 1997.
8. Calvo F, Brower M and Carney DN: Continuous culture and soft agarose cloning of multiple human breast carcinoma cell lines in serum-free medium. Cancer Res 44: 4553-4559, 1984.
9. Knutson KL, Schiffman K and Disis ML: Immunization with a HER-2/neu helper peptide vaccine generates HER- 2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107: 477-484, 2001.
10. Eggert AO, Becker JC, Ammon M, McLellan AD, Renner G, Merkel A, Brocker EB and Kampgen E: Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture. Eur J Immunol 32: 122-127, 2002.
11. Ikuta Y, Okugawa T, Furugen R, Nagata Y, Takahashi Y, Wang L, Ikeda H, Watanabe M, Imai S and Shiku H: A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes. Int J Cancer 87: 553-558, 2000.
12. Warrens AN, Lombardi G and Lechler RI: Presentation and recognition of major and minor histocompatibility antigens. Transpl Immunol 2: 103-107, 1994.
13. Bernhard H, Maeurer M J, Jager E, Wolfel T, Schneider J, Karbach J, Seliger B, Huber C, Storkus WS, Lotze MT, Meyer zum Buschenfelde KH and Knuth A: Recognition of human renal cell carcinoma and melanoma by HLA-A2 restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma. Scand J Immunol 44: 285-292, 1996.
14. Zhao X, Wei YQ and Peng ZL: Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed DC. Immunol Invest 30: 33-45, 2001.
15. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty LE, Richards JM and Bartolucci AA: A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 75: 34-42, 1995.
16. Alters SE, Gadea JR and Philip R: Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells. In: Castagnoli R (ed): Dendritic Cells in Fundamental and Clinical Immunology. Plenum Press, NY, 1997, 519-524.
17. Pupa SM, Menard S, Andreola S and Colnaghi MI: Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res 53: 5864-5866, 1993.
18. Kotera Y, Fontenot JD, Pecher G, Metzgar RS and Finn OJ: Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54: 2856-2860, 1994.
19. Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, Verstraeten AA, Litvinov SV, van Kamp GJ, Meijer S, Vermorken J and Hilgers J: Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur J Cancer 32A: 1325-1331, 1996.